Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.41
Bid: 1.41
Ask: 1.43
Change: -0.02 (-1.40%)
Spread: 0.02 (1.418%)
Open: 1.41
High: 1.41
Low: 1.41
Prev. Close: 1.43
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of Transfer

6 Aug 2021 07:00

RNS Number : 7629H
RTW Venture Fund Limited
06 August 2021
 

LEI: 549300Q7EXQQH6KF7Z84

 

6 August 2021

RTW VENTURE FUND LIMITED

 (the "Company")

 

Completion of Transfer of Ordinary Shares to the Premium Segment of the London Stock Exchange and Introduction of Sterling Quote

Further to its announcement on 5 August 2021, RTW Venture Fund Limited (the "Company") is pleased to announce the admission of all of its ordinary shares (the "Ordinary Shares") to listing on the Official List of the Financial Conduct Authority and to trading on the Premium Segment of the London Stock Exchange plc's Main Market ("Admission"). The application for Admission was approved by shareholder vote at the extraordinary general meeting held on 30 July 2021.

Admission will become effective at 8:00am today. The Company's existing ticker, ISIN and SEDOL will remain unchanged.

The Company is pleased to confirm an additional market quote for the shares on the London Stock Exchange denominated in GBP (the "GBP Quote"), in connection with which the Company has introduced a new ticker and SEDOL with effect from 8:00 a.m. today, as set out below. The GBP Quote will appear alongside the Company's existing USD market quote (the "USD Quote") and there will be no changes to the legal form or nature of the Company's shares nor to the reporting currency of the Company's financial statements or the NAV (which will remain in USD). 

 

 

USD Quote

GBP Quote

ISIN

GG00BKTRRM22

GG00BKTRRM22

SEDOL

BKTRRM2

BNNXVW5

Ticker

RTW LN

RTWG LN

 

 

For further information please contact:

For Further Information

RTW Investments, LP +1 (646) 597 6980Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Senior Business Development Associate

 

Elysium Fund Management Limited +44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

 

J.P. Morgan Cazenove +44 (0)20 7742 4000

William Simmonds / Jérémie Birnbaum (Corporate Finance)

James Bouverat / Liam MacDonald-Raggett (Sales)

 

Barclays +44 (0)20 7623 2323

Tom Swerling

Andrew Tusa

 

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKPBQPBKDNFK
Date   Source Headline
18th Jun 20214:40 pmRNSSecond Price Monitoring Extn
18th Jun 20214:35 pmRNSPrice Monitoring Extension
16th Jun 20217:00 amRNSIssue of Equity
15th Jun 202112:05 pmRNSNew Investment in Umoja Biopharma
14th Jun 20212:32 pmRNSAnnouncement of Share Issuance
14th Jun 20217:00 amRNSNet Asset Value(s)
9th Jun 202112:05 pmRNSNew Investment in Alcyone Therapeutics
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20211:05 pmRNSAdditional Investment in Portfolio Company
20th May 20218:05 amRNSNew Investment in Numab Therapeutics
14th May 20217:00 amRNSNet Asset Value(s)
29th Apr 20217:00 amRNSAnnual Financial Report
28th Apr 20217:00 amRNSQuarterly Update
19th Apr 20217:00 amRNSPortfolio Company Update: Biomea IPO
15th Apr 20217:00 amRNSNet Asset Value(s)
1st Apr 20217:05 amRNSTotal Voting Rights
1st Apr 20217:00 amRNSNotice of Annual Report
30th Mar 20211:00 pmRNSNew Investment in Pyxis Oncology
17th Mar 20217:00 amRNSIssue of Equity
15th Mar 20217:01 amRNSAnnouncement of Share Issuance
15th Mar 20217:00 amRNSPortfolio Company Update: Prometheus IPO
12th Mar 202112:30 pmRNSNew Investment in Monte Rosa Therapeutics
12th Mar 20217:00 amRNSNet Asset Value(s)
9th Mar 20211:45 pmRNSNew Investment in Ventyx Biosciences
9th Mar 202112:45 pmRNSNew Investment in Visus Therapeutics
1st Mar 20211:00 pmRNSNew Investment in Tenaya Therapeutics
1st Mar 20217:00 amRNSTotal Voting Rights
26th Feb 20211:15 pmRNSNew Investment in Artiva Biotherapeutics
18th Feb 20217:00 amRNSIssue of Equity
15th Feb 20214:10 pmRNSAnnouncement of Share Issuance
15th Feb 20217:00 amRNSNet Asset Value(s)
8th Feb 20217:00 amRNSPortfolio Company Update: Immunocore IPO
5th Feb 20217:00 amRNSPortfolio Company Update: Landos IPO
1st Feb 20217:00 amRNSChange of Administrator and Company Secretary
1st Feb 20217:00 amRNSTotal Voting Rights
25th Jan 202110:04 amRNSDirector/PDMR Shareholding
22nd Jan 20217:00 amRNSQuarterly Update
19th Jan 20216:11 pmRNSIssue of Equity
15th Jan 20213:39 pmRNSAnnouncement of Share Issuance
15th Jan 20217:00 amRNSNet Asset Value
11th Jan 202112:22 pmRNSAdditional Investment in Portfolio Company
6th Jan 20213:30 pmRNSNew Investment in Biomea Fusion
29th Dec 202010:16 amRNSDirector/PDMR Shareholding
24th Dec 20208:35 amRNSDirector/PDMR Shareholding
23rd Dec 20209:07 amRNSDirector/PDMR Shareholding
14th Dec 20207:00 amRNSNet Asset Value(s)
10th Dec 20207:00 amRNSTransformational Update from Largest Holding
8th Dec 20208:03 amRNSNew Investment in Nuance Pharma
1st Dec 20207:00 amRNSTotal Voting Rights
16th Nov 20205:59 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.